Article Text

Download PDFPDF
Why should we screen for atrial fibrillation?

Statistics from


  • Contributors ES and JE contributed equally to this manuscript.

  • Competing interests ES has received lecture fees from MSD, Bristol-Myers Squibb-Pfizer, Boehringer-Ingelheim and Sanofi and a research grant from Boehringer-Ingelheim. JE has received consultancy fees from Sanofi and Pfizer, lecture fees from Astra Zeneca, Boehringer-Ingelheim, Medtronic and Bristol-Myers Squibb and travel expenses from Boehringer-Ingelheim and Sanofi.

  • Provenance and peer review Commissioned; internally peer reviewed.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Linked Articles